Abbott Laboratories Corporation

Mary Katherin Verzal

Philip R Kym

Anil Vasudevan

Ju Gao

Andrew J Souers

Michael A Patane

Matthew J LaMarche

Rajesh R Iyengar

Martin P Maguire

Irini Akritopoulou-Zanze

Su-Jen Lai

Mathew M Mulhern

Courtney A Cullis

Christopher Blackburn

Dariusz Wodka

Kresna Hartandi

Christine Ann Collins

John K Lynch

Jennifer C Freeman

James A Brown

Kathleen M Phelan

Jennifer L Che

This invention provides compounds that are antagonists of melanin concentrating hormone receptor-1 (MCH-R1). The compounds are represented by formula I:where m is zero or one, n is zero to two, Y is oxygen or &#x2014;N(R)&#x2014;, R, R, R, R, R, Rand Ring A are defined in the specification. Coumarin and quinolone compounds where Rand Rtogether form a fused benzo ring are preferred. The invention also provides compounds of formula VI where the coumarin moiety is replaced by a quinazolinone ring. The compounds are useful for treating MCH-R1-related disorders, particularly overweight conditions including obesity.

Antagonists of melanin concentrating hormone receptor

The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.

Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor

Growing community of inventors

Burlington, WI, United States of America

Mary Katherin Verzal